Chimerix, Inc. (CMRX)
NASDAQ: CMRX · IEX Real-Time Price · USD
0.900
0.00 (-0.01%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Chimerix Revenue
Chimerix had revenue of $41.00K in the twelve months ending March 31, 2024. In the year 2023, Chimerix had annual revenue of $324.00K.
Revenue (ttm)
$41.00K
Revenue Growth
-99.88%
P/S Ratio
1,967.27
Revenue / Employee
$569
Employees
72
Market Cap
80.66M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 324.00K | -33.50M | -99.04% |
Dec 31, 2022 | 33.82M | 31.85M | 1,609.15% |
Dec 31, 2021 | 1.98M | -3.39M | -63.16% |
Dec 31, 2020 | 5.37M | -7.15M | -57.09% |
Dec 31, 2019 | 12.52M | 5.30M | 73.49% |
Dec 31, 2018 | 7.22M | 2.72M | 60.57% |
Dec 31, 2017 | 4.49M | -1.21M | -21.19% |
Dec 31, 2016 | 5.70M | -5.06M | -47.02% |
Dec 31, 2015 | 10.76M | 6.72M | 166.39% |
Dec 31, 2014 | 4.04M | -330.00K | -7.55% |
Dec 31, 2013 | 4.37M | -29.35M | -87.04% |
Dec 31, 2012 | 33.72M | 21.62M | 178.65% |
Dec 31, 2011 | 12.10M | 10.39M | 605.60% |
Dec 31, 2010 | 1.72M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SCYNEXIS | 140.39M |
Protalix BioTherapeutics | 59.65M |
DBV Technologies | 14.94M |
Ikena Oncology | 3.85M |
Serina Therapeutics | 3.15M |
Nutriband | 2.02M |
CMRX News
- 16 days ago - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update - GlobeNewsWire
- 3 months ago - Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 - GlobeNewsWire
- 5 months ago - Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update - GlobeNewsWire
- 5 months ago - Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024 - GlobeNewsWire
- 7 months ago - Chimerix Appoints Lisa Decker to Board of Directors - GlobeNewsWire
- 8 months ago - Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer - GlobeNewsWire